Vibha Agrawal
Pain Management · Pasadena
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 33 years
- Graduated 1993
Offices
1 location · Algos Inc A Medical Corporation · 24 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Vibha Agrawal’s office at (626) 403-6200 to ask if they take your plan before you enroll.
California Medical Board record
Licence C135409 · Current
Licensed to practise in California · since 2015 · expires 2028-07-31 · University of Allahabad, M.L.N. Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Physical Medicine and Rehabilitation - Pain Medicine
Original Medicare doctor bills
$7,597
Medicare paid this office $7,597 for 37 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 25 | $3,776 | $94 |
| Short return visit (20+ min) | 13 | $1,729 | $79 |
| Injection of trigger points, 3 or more muscles | 14 | $1,093 | $50 |
Procedures year by year
| Procedure | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Injection of trigger points, 3 or more muscles | – | – | – | – | – | 22 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
37 Original Medicare patients in 2024. Average age 65 · Women 62% · Health risk score 1.34. At or below the middle of the specialty; the typical pain management clinician is at 1.38.
Conditions among them: High blood pressure 65% · Diabetes 54% · Coronary heart disease 32% · Depression 32%.
The office billed $32,708, Medicare allowed $10,579 and paid $7,597; for 96 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 37 | 96 | 65 | 1.34 | $32,708 | $7,597 |
| 2023 | 19 | 33 | 68 | 1.30 | $10,337 | $2,022 |
| 2022 | 33 | 94 | 68 | 1.34 | $39,445 | $6,449 |
| 2021 | 39 | 154 | 66 | 1.23 | $71,105 | $13,396 |
| 2019 | 24 | 95 | 68 | 1.47 | $45,927 | $6,015 |
| 2018 | 49 | 200 | 69 | 2.11 | $107,288 | $15,445 |
| 2017 | 26 | 88 | 68 | 1.34 | $37,907 | $7,113 |
| 2016 | 34 | 87 | 67 | 1.71 | $31,500 | $8,039 |
| 2014 | 23 | 46 | 65 | 0.93 | $7,310 | $3,076 |
| 2013 | 61 | 251 | 58 | 1.10 | $40,467 | $16,046 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2022: 3 services
| Return visit (30+ min) | 21 | $2,718 | $105 |
| Short return visit (20+ min) | 18 | $2,494 | $53 |
| Testing for presence of drug, by chemistry analyzers | 11 | $920 | $61 |
2021: 3 services
| Short return visit (20+ min) | 20 | $5,436 | $81 |
| Return visit (30+ min) | 24 | $4,251 | $112 |
| Testing for presence of drug, by chemistry analyzers | 26 | $2,143 | $61 |
2019: 3 services
| Return visit (30+ min) | 18 | $2,457 | $82 |
| Short return visit (20+ min) | 14 | $1,831 | $51 |
| Testing for presence of drug, by chemistry analyzers | 15 | $1,394 | $63 |
2018: 4 services
| Return visit (30+ min) | 33 | $6,035 | $90 |
| Short return visit (20+ min) | 24 | $3,790 | $57 |
| New patient visit (45+ min) | 29 | $3,444 | $119 |
| Testing for presence of drug, by chemistry analyzers | 16 | $1,267 | $70 |
2017: 3 services
| Return visit (30+ min) | 16 | $3,285 | $86 |
| Short return visit (20+ min) | 13 | $1,720 | $57 |
| New patient visit (45+ min) | 13 | $1,700 | $131 |
2016: 2 services
| New patient visit (45+ min) | 22 | $2,961 | $135 |
| Return visit (30+ min) | 17 | $2,760 | $92 |
2014: 1 service
| Short return visit (20+ min) | 15 | $995 | $50 |
2013: 3 services
| Return visit (30+ min) | 33 | $6,572 | $77 |
| Short return visit (20+ min) | 38 | $5,467 | $47 |
| New patient visit (45+ min) | 28 | $2,969 | $106 |
Medicaid work
$18,304 in 2024
Medicaid paid $18,304 for 661 billed services this clinician did in 2024, up to 45 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 240 | $7,720 |
| Injection(s); single or multiple trigger point(s), 3 or more muscles | 298 | $7,467 |
| New patient visit (45+ min) | 40 | $1,703 |
| Short return visit (20+ min) | 55 | $1,330 |
| Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; first 30 minutes | 28 | $84 |
| 2024 | 661 | 5 | 45 | $18,304 |
| 2023 | 520 | 5 | 39 | $15,812 |
| 2022 | 429 | 4 | 43 | $11,830 |
| 2021 | 433 | 4 | 39 | $10,958 |
| 2019 | 18 | 1 | 18 | $524 |
| 2018 | 42 | 2 | 14 | $1,939 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 166 | $5,437 |
| Injection(s); single or multiple trigger point(s), 3 or more muscles | 168 | $5,149 |
| Short return visit (20+ min) | 76 | $2,487 |
| New patient visit (45+ min) | 61 | $2,318 |
| Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; first 30 minutes | 49 | $420 |
2022
| Return visit (30+ min) | 182 | $5,053 |
| Short return visit (20+ min) | 131 | $2,808 |
| New patient visit (45+ min) | 69 | $2,627 |
| Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service | 47 | $1,341 |
2021
| Short return visit (20+ min) | 163 | $3,588 |
| Return visit (30+ min) | 143 | $3,519 |
| New patient visit (45+ min) | 101 | $3,105 |
| Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service | 26 | $746 |
2019
| Return visit (30+ min) | 18 | $524 |
2018
| Return visit (30+ min) | 29 | $1,031 |
| Injection(s); single or multiple trigger point(s), 3 or more muscles | 13 | $908 |
Drugs they prescribed that Part D paid
$79,354
Pharmacies billed $79,354 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 20% of their Part D prescriptions (164 of 816) in 2024. At or below the middle of the specialty; the typical pain management clinician is at 44%. Long-acting opioids: 30% of their opioid prescriptions.
725 generic and 91 brand-name prescriptions · $79,354 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Belbuca | 29 | $23,959 | $826 |
| Licart | 19 | $15,194 | $800 |
| Ztlido | 13 | $4,507 | $347 |
| Lidocaine | 50 | $4,212 | $84 |
| Diclofenac | 78 | $3,814 | $49 |
See all 18 drugs
| Belbuca | 29 | $23,959 | $826 |
| Licart | 19 | $15,194 | $800 |
| Ztlido | 13 | $4,507 | $347 |
| Lidocaine | 50 | $4,212 | $84 |
| Diclofenac | 78 | $3,814 | $49 |
| Buprenorphine | 17 | $1,776 | $104 |
| Gabapentin | 146 | $1,208 | $8 |
| Pregabalin | 44 | $911 | $21 |
| Duloxetine | 61 | $848 | $14 |
| Naloxone | 13 | $628 | $48 |
| Acetaminophen-Codeine | 16 | $326 | $20 |
| Hydrocodone-Acetaminophen | 34 | $310 | $9 |
| Tizanidine | 62 | $274 | $4 |
| Celecoxib | 19 | $213 | $11 |
| Methocarbamol | 33 | $202 | $6 |
| Tramadol | 50 | $161 | $3 |
| Nortriptyline | 11 | $134 | $12 |
| Naproxen | 15 | $97 | $6 |
Year by year
| 2024 | 816 | 158 | 20% (164) | 11% | $79,354 |
| 2023 | 898 | 192 | 24% (214) | 8% | $74,263 |
| 2022 | 1,280 | 183 | 30% (388) | 10% | $108,217 |
| 2021 | 762 | 113 | 35% (269) | 12% | $77,685 |
| 2019 | 744 | 139 | 39% (291) | 8% | $33,922 |
| 2018 | 1,301 | 239 | 41% (531) | 10% | $59,500 |
| 2017 | 1,656 | 339 | 43% (716) | 8% | $78,968 |
| 2016 | 638 | 192 | 46% (292) | 8% | $26,197 |
| 2015 | 17 | 13 | None | None | $406 |
| 2014 | 65 | 11 | 45% (29) | 17% | $4,155 |
| 2013 | 433 | 49 | 55% (236) | 14% | $26,714 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Belbuca | 24 | $19,421 | $809 |
| Diclofenac | 136 | $14,502 | $107 |
| Licart | 15 | $11,952 | $797 |
| Buprenorphine | 20 | $4,229 | $211 |
| Duloxetine | 110 | $3,554 | $32 |
| Naloxone | 20 | $1,571 | $79 |
| Lidocaine | 22 | $1,567 | $71 |
| Hydrocodone-Acetaminophen | 59 | $1,484 | $25 |
| Pregabalin | 38 | $1,418 | $37 |
| Gabapentin | 170 | $1,336 | $8 |
| Tizanidine | 27 | $598 | $22 |
| Acetaminophen-Codeine | 30 | $596 | $20 |
| Tramadol | 57 | $241 | $4 |
| Nabumetone | 15 | $146 | $10 |
| Methocarbamol | 19 | $108 | $6 |
| Cyclobenzaprine | 25 | $102 | $4 |
| Amitriptyline | 11 | $31 | $3 |
2022: 23 drugs
| Oxycontin | 34 | $17,827 | $524 |
| Belbuca | 24 | $17,247 | $719 |
| Diclofenac | 164 | $16,412 | $100 |
| Buprenorphine | 26 | $6,954 | $267 |
| Buprenorphine-Naloxone | 19 | $3,908 | $206 |
| Hydrocodone-Acetaminophen | 156 | $3,744 | $24 |
| Lidocaine | 20 | $2,707 | $135 |
| Duloxetine | 110 | $2,470 | $22 |
| Gabapentin | 220 | $2,009 | $9 |
| Naloxone | 15 | $1,422 | $95 |
| Pregabalin | 38 | $984 | $26 |
| Baclofen | 52 | $666 | $13 |
| Acetaminophen-Codeine | 34 | $476 | $14 |
| Tizanidine | 23 | $358 | $16 |
| Amitriptyline | 21 | $320 | $15 |
| Oxycodone | 16 | $258 | $16 |
| Tramadol | 58 | $257 | $4 |
| Naproxen | 25 | $160 | $6 |
| Cyclobenzaprine | 16 | $112 | $7 |
| Methocarbamol | 17 | $99 | $6 |
| Ibuprofen | 18 | $97 | $5 |
| Omeprazole | 22 | $78 | $4 |
| Meloxicam | 12 | $51 | $4 |
2021: 19 drugs
| Oxycontin | 34 | $35,828 | $1,054 |
| Movantik | 11 | $4,019 | $365 |
| Buprenorphine | 11 | $3,751 | $341 |
| Hydrocodone-Acetaminophen | 115 | $2,739 | $24 |
| Narcan | 20 | $2,581 | $129 |
| Lidocaine | 11 | $2,494 | $227 |
| Buprenorphine-Naloxone | 13 | $1,851 | $142 |
| Oxycodone-Acetaminophen | 25 | $1,717 | $69 |
| Duloxetine | 68 | $1,555 | $23 |
| Diclofenac | 38 | $1,407 | $37 |
| Gabapentin | 109 | $1,153 | $11 |
| Pregabalin | 18 | $948 | $53 |
| Oxycodone | 23 | $474 | $21 |
| Amitriptyline | 15 | $393 | $26 |
| Tizanidine | 26 | $321 | $12 |
| Baclofen | 14 | $304 | $22 |
| Ibuprofen | 20 | $268 | $13 |
| Methocarbamol | 12 | $135 | $11 |
| Tramadol | 21 | $104 | $5 |
2019: 17 drugs
| Lyrica | 18 | $9,782 | $543 |
| Gabapentin | 177 | $2,943 | $17 |
| Hydrocodone-Acetaminophen | 113 | $2,168 | $19 |
| Morphine Sulfate Er | 51 | $1,879 | $37 |
| Diclofenac | 36 | $1,737 | $48 |
| Narcan | 13 | $1,631 | $125 |
| Duloxetine | 19 | $872 | $46 |
| Nabumetone | 17 | $546 | $32 |
| Oxycodone-Acetaminophen | 29 | $537 | $19 |
| Baclofen | 20 | $343 | $17 |
| Cyclobenzaprine | 22 | $251 | $11 |
| Morphine Sulfate | 12 | $223 | $19 |
| Tramadol | 28 | $158 | $6 |
| Naproxen | 22 | $150 | $7 |
| Trazodone | 21 | $145 | $7 |
| Tizanidine | 14 | $132 | $9 |
| Alendronate | 11 | $87 | $8 |
2018: 24 drugs
| Lyrica | 23 | $13,698 | $596 |
| Diclofenac | 78 | $5,036 | $65 |
| Gabapentin | 356 | $4,921 | $14 |
| Buprenorphine | 12 | $3,495 | $291 |
| Morphine Sulfate Er | 85 | $3,297 | $39 |
| Hydrocodone-Acetaminophen | 158 | $2,819 | $18 |
| Voltaren | 22 | $2,562 | $116 |
| Oxycodone-Acetaminophen | 82 | $2,446 | $30 |
| Duloxetine | 24 | $2,207 | $92 |
| Fentanyl | 15 | $1,471 | $98 |
| Morphine Sulfate | 25 | $807 | $32 |
| Tramadol | 81 | $439 | $5 |
| Baclofen | 22 | $366 | $17 |
| Naproxen | 55 | $359 | $7 |
| Celecoxib | 17 | $302 | $18 |
| Hydromorphone | 15 | $256 | $17 |
| Oxycodone | 11 | $192 | $17 |
| Amitriptyline | 16 | $174 | $11 |
| Acetaminophen-Codeine | 11 | $169 | $15 |
| Meloxicam | 19 | $153 | $8 |
| Ibu | 15 | $135 | $9 |
| Trazodone | 22 | $117 | $5 |
| Ibuprofen | 12 | $117 | $10 |
| Tizanidine | 16 | $108 | $7 |
2017: 25 drugs
| Lyrica | 46 | $24,492 | $532 |
| Oxycontin | 17 | $6,950 | $409 |
| Gabapentin | 482 | $6,199 | $13 |
| Diclofenac | 101 | $5,939 | $59 |
| Duloxetine | 53 | $5,647 | $107 |
| Oxycodone-Acetaminophen | 136 | $5,330 | $39 |
| Hydrocodone-Acetaminophen | 271 | $4,163 | $15 |
| Morphine Sulfate Er | 65 | $3,437 | $53 |
| Buprenorphine | 11 | $2,898 | $263 |
| Diclofenac | 28 | $1,002 | $36 |
| Celecoxib | 18 | $760 | $42 |
| Morphine Sulfate | 14 | $760 | $54 |
| Tramadol | 99 | $507 | $5 |
| Tramadol Hcl-Acetaminophen | 25 | $378 | $15 |
| Baclofen | 18 | $336 | $19 |
| Tizanidine | 33 | $268 | $8 |
| Hydromorphone | 12 | $228 | $19 |
| Oxycodone | 20 | $218 | $11 |
| Acetaminophen-Codeine | 20 | $209 | $10 |
| Methylprednisolone | 14 | $201 | $14 |
| Naproxen | 23 | $177 | $8 |
| Methocarbamol | 18 | $126 | $7 |
| Diazepam | 12 | $110 | $9 |
| Meloxicam | 15 | $75 | $5 |
| Trazodone | 12 | $58 | $5 |
2016: 14 drugs
| Lyrica | 22 | $9,393 | $427 |
| Oxycontin | 12 | $4,583 | $382 |
| Hydrocodone-Acetaminophen | 129 | $2,463 | $19 |
| Gabapentin | 182 | $2,147 | $12 |
| Oxycodone-Acetaminophen | 29 | $1,745 | $60 |
| Duloxetine | 31 | $1,502 | $48 |
| Morphine Sulfate Er | 18 | $744 | $41 |
| Fentanyl | 11 | $624 | $57 |
| Diclofenac | 19 | $554 | $29 |
| Tizanidine | 16 | $298 | $19 |
| Tramadol | 43 | $181 | $4 |
| Acetaminophen-Codeine | 19 | $170 | $9 |
| Naproxen | 13 | $63 | $5 |
| Alendronate | 11 | $30 | $3 |
2014: 2 drugs
| Oxycodone | 12 | $225 | $19 |
| Gabapentin | 22 | $194 | $9 |
2013: 13 drugs
| Oxycontin | 33 | $8,756 | $265 |
| Oxycodone | 74 | $2,730 | $37 |
| Fentanyl | 18 | $2,251 | $125 |
| Lyrica | 15 | $1,728 | $115 |
| Oxycodone Hcl-Acetaminophen | 29 | $1,472 | $51 |
| Hydrocodone-Acetaminophen | 30 | $1,151 | $38 |
| Oxycodone-Acetaminophen | 32 | $849 | $27 |
| Gabapentin | 48 | $776 | $16 |
| Diclofenac | 18 | $500 | $28 |
| Cyclobenzaprine | 47 | $398 | $8 |
| Morphine Sulfate Er | 13 | $331 | $25 |
| Tizanidine | 16 | $199 | $12 |
| Fluoxetine | 11 | $191 | $17 |
Money from drug and device companies
$430 in 2025
| 2025 | 6 | 18 | None | $430 |
| 2024 | 9 | 27 | None | $545 |
| 2023 | 5 | 14 | None | $358 |
| 2022 | 3 | 3 | None | $53 |
| 2021 | 1 | 1 | None | $21 |
| 2019 | 5 | 5 | None | $93 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| IBSA Pharma | Tirosint | $195 | 8 payments
|
| Vertex Pharmaceuticals | Journavx | $94 | 3 payments
|
| Collegium Pharmaceutical | Belbuca | $55 | 3 payments
|
| Biotronik Nro | Prospera | $37 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Relistor | $33 | 2 payments
|
| Virtus Pharmaceuticals | Levorphanol Tartrate | $16 | 1 payment
|
See all 18 published payments
| IBSA Pharma | Meals · 2025-12-05 | Tirosint | $23 |
| Collegium Pharmaceutical | Meals · 2025-10-30 | Belbuca | $20 |
| Biotronik Nro | Meals · 2025-10-22 | Prospera | $37 |
| IBSA Pharma | Meals · 2025-10-21 | Tirosint | $23 |
| IBSA Pharma | Meals · 2025-09-23 | Tirosint | $22 |
| Vertex Pharmaceuticals | Meals · 2025-09-18 | Journavx | $35 |
| IBSA Pharma | Meals · 2025-08-29 | Tirosint | $59 |
| IBSA Pharma | Meals · 2025-08-21 | Tirosint | $24 |
| IBSA Pharma | Meals · 2025-08-21 | Tirosint | $4 |
| Virtus Pharmaceuticals | Meals · 2025-08-14 | Levorphanol Tartrate | $16 |
| IBSA Pharma | Meals · 2025-08-01 | Tirosint | $16 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-07-14 | Relistor | $15 |
| Vertex Pharmaceuticals | Meals · 2025-06-12 | Journavx | $33 |
| Collegium Pharmaceutical | Meals · 2025-05-01 | Belbuca | $15 |
| Vertex Pharmaceuticals | Meals · 2025-03-27 | Journavx | $27 |
| IBSA Pharma | Meals · 2025-01-23 | Tirosint | $24 |
| Collegium Pharmaceutical | Meals · 2025-01-22 | Belbuca | $20 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-01-14 | Relistor | $18 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $545
| Salix Pharmaceuticals a division of Bausch Health US | Relistor | $156 | 10 payments
|
| Vertex Pharmaceuticals | None | $113 | 5 payments
|
| IBSA Pharma | Tirosint | $93 | 4 payments
|
| Virtus Pharmaceuticals | Levorphanol Tartrate | $74 | 3 payments
|
| Nalu Medical | Nalu Neurostimulation System | $37 | 1 payment
|
| Biotronik Nro | Prospera | $21 | 1 payment
|
| Scilex Pharmaceuticals | Ztlido | $19 | 1 payment
|
| Abbvie | Ubrelvy | $17 | 1 payment
|
| Collegium Pharmaceutical | Belbuca | $15 | 1 payment
|
2023: $358
| IBSA Pharma | Licart | $228 | 8 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Relistor | $54 | 3 payments
|
| AbbVie | Qulipta | $31 | 1 payment
|
| Collegium Pharmaceutical | Belbuca | $24 | 1 payment
|
| Virtus Pharmaceuticals | Levorphanol Tartrate | $21 | 1 payment
|
2022: $53
| Nevro | Omnia | $25 | 1 payment
|
| DePuy Synthes Sales | Orthovisc | $15 | 1 payment
|
| Boston Scientific | Superion Indirect Decompression System | $13 | 1 payment
|
2021: $21
| BioDelivery Sciences International | Belbuca | $21 | 1 payment
|
2019: $93
| Assertio Therapeutics | Zipsor | $23 | 1 payment
|
| Scilex Pharmaceuticals | Ztlido 30 Pouch in 1 Carton 1 Patch in 1 Pouch | $22 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Relistor | $20 | 1 payment
|
| Lilly USA | Emgality | $18 | 1 payment
|
| Boston Scientific | General Pain Management | $11 | 1 payment
|
Professional record
- NPI
- 1528196045
- Licence
- CA C135409, WI 52154-020California C135409: Current · expires 2028-07-31
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2081P2900X (2081P2900X)
- Mailing address
- 1017 S Fair Oaks Ave, Pasadena, CA, 91105
- NPI first listed
- 2007-02-28
- NPI last updated
- 2026-08-28
- NPI record certified
- 2026-08-28
This is when the NPI record was last certified, not a medical board exam.